IVF Gets AI Help as Robots Enter the Lab

AI and robots are moving into IVF labs to standardize treatment and lift success. The MIT Technology Review reports a wave of AI tools, robots, PGT, and gene editing trials reshaping assisted reproduction. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

IVF remains slow, painful, and expensive for many, and success rates have declined in recent years. The article notes that while IVF has improved enormously since Louise Brown’s birth, it is not perfect and access is unequal. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

Embryologists and gynecologists still struggle to explain why many healthy-looking embryos fail to implant in the uterus, underscoring how much about reproduction remains uncertain. The article highlights the knowledge gaps that new tech hopes to address. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

To tackle those gaps, researchers are piloting technologies designed to standardize treatment, eliminate human error, boost success rates, and make IVF more accessible, even as debates about how genetic tools should be used intensify. The piece argues these tools could usher in a new era for assisted reproduction, aided by AI and robotics. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

A glimpse of the future is in Valencia, Spain, where researchers at the Carlos Simon Foundation are testing lab technologies and showed a device that has been used to keep a human uterus alive outside the body. The field is already moving toward devices and protocols that could standardize conditions across clinics. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

The article also notes the ethical questions surrounding how AI aided embryo analysis and potential gene editing will be used, signaling that the tech race comes with a serious moral map to navigate. As tools advance, policymakers and clinicians will wrestle with where to draw lines and what safeguards are required. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

For product teams and clinics eyeing this space, the practical takeaway is that AI and automation could cut run-to-run variation and help standardize protocols, but adoption hinges on cost, regulatory clearance, and robust cross-clinic validation. The article frames a future where reliable data and clear ethics are as important as the hardware. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/

Industry practitioners should watch three things: cost and regulatory hurdles that will slow adoption, new failure modes as automation handles delicate biological processes, and the need for transparent, independent evaluation across clinics to avoid cherry-picked results. These are not trivial roadblocks, but they are tractable with careful design and governance. https://www.technologyreview.com/2026/05/07/1136946/whats-next-for-ivf-ai-robot-pgt-gene-editing/